Haemonetics (HAE) Soars 38.27% on Q3 Earnings, Margin Expansion Drives 7-Day Rally

The share price rose to its highest level so far this month today, with an intraday gain of 6.35%. The stock has climbed 38.27% over the past seven days, marking a sustained rally following strong third-quarter earnings and operational improvements. Haemonetics (HAE) closed at a seven-day high after outperforming revenue and earnings expectations, signaling renewed investor confidence in its ability to navigate sector-specific challenges.

Haemonetics’ recent surge was driven by its Q3 2025 results, which showed organic revenue declining 1.8% year-over-year—well ahead of the 5.3% drop in total revenue—to $327.3 million. Adjusted earnings per share surged 14.3% to $1.27, surpassing estimates, while operating margins expanded to 17.9% from 15% in the prior year. The company also raised full-year adjusted EPS guidance to $4.90, reflecting improved cost management and a shift toward high-margin products like its Hemostasis Management line. These gains were offset by weaker performance in the Plasma segment due to customer transitions and the divestiture of its Whole Blood product line.

Despite near-term headwinds, Haemonetics’ focus on operational efficiency and strategic acquisitions has bolstered its resilience. Free cash flow reached $106.3 million in Q3, with a 32.5% margin, enabling share repurchases that have reduced the float by 6.7% over five years. Analysts project flat revenue for the next 12 months, though the company’s recent margin expansion and software-driven solutions for blood processing position it to capitalize on digital healthcare trends. The stock’s 22.1% jump post-earnings contrasts with a 16.9% year-to-date decline, highlighting mixed investor sentiment amid sector volatility and macroeconomic risks.